A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.
VB4-845 的 I 期临床研究：每周对头颈部鳞状细胞癌患者进行瘤内注射抗 EpCAM 重组融合蛋白
期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/dddt.s3442
MacDonald Glen C, Rasamoelisolo Michèle, Entwistle Joycelyn, Cizeau Jeannick, Bosc Denis, Cuthbert Wendy, Kowalski Mark, Spearman Maureen, Glover Nick
